sopsi         

Loading

L. Moretti, G. Perugi - Vol. 6, Settembre 2000, num.3

Testo Immagini Bibliografia Summary Riassunto Indice

Depressione e disturbi d'ansia nella malattia di Parkinson. Implicazioni cliniche e terapeutiche
Depression and anxiety disorders in Parkinson's disease. Clinical and therapeutic implications

1 Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ.
Depressive symptoms in Parkinson’s disease, a comparison with disabled control subjects.
 J Geriatr Psychiatry Neurol 1990;2:3-9.

2 Cummings JL.
 Depression and Parkinson’s disease: a review.
Am J Psychiatry 1992;149:443-54.

3 Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG.
Cognitive impairments and depression in Parkinson’s disease: a follow-up study.
 J Neurol Neurosurg Psychiatry 1990;53:597-602.

4 Mayeux R, Stern Y, Cote L, Williams JB.
Altered serotonin metabolism in depressed patients with Parkinson’s disease.
 Neurology 1984;34:642-6.

5 Gotham AM, Brown RG, Marsden CD.
Depression in Parkinson’s disease: a quantitative and qualitative analysis.
 J Neurol Neurosurg Psychiatry 1986;49:381-9.

6 Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R.
An estimate of the incidence of depression in idiopathic Parkinson’s disease.
 Arch Neurol 1992;49:305-7.

7 Menza MA, Mark MH.
Parkinson’s disease and depression: the relationship to disability and personality.
 J Neuropsychiatry 1994;6:165-9.

8 Gangat AE, Simpson MA, Naidoo LR.
Medication as a potential cause of depression.
 S Afr Med J 1986;70:224-6.

9 Mayberg HS, Solomon DH.
Depression in PD: a biochemical and organic viewpoint.
 In: Weiner WJ, ed. Behavioral Neurology of Movement Disorders. Adv Neurology 1995;65.

10 Mayeux R, Stern Y, Sano M, Williams JB, Cote LJ.
The relationship of serotonin to depression in Parkinson’s disease.
 Mov Disord 1988;3:237-44.

11 Cantello R, Aguggia M, Gilli M, Delsedime M, Chiardo Cutin I, Riccio A, et al.
Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.
 J Neurol Neurosurg Psychiatry 1989;52:724-31.

12 Fibiger HC.
The neurobiological substrates of depression in Parkinson’s disease: a hypothesis.
 Can J Neurol Sci 1984;11:105-7.

13 Torack RM, Morris JC.
The association of ventral tegmental area histopathology with adult dementia.
 Arch Neurol 1988;45:211-8.

14 Jellinger K.
Overview of morphological changes in Parkinson’s disease.
 In: Yahr MD, Bergmann KJ, eds. Advances in Neurology: Parkinson’s Disease. New York: Raven 1987:1-18.

15 Uhl GR, Hedreen JC, Price DL.
Parkinson’s disease: loss of neurons from the ventral tegmental area controlateral to therapeutic surgical lesions.
 Neurology 1985;35:1215-8.

16 Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, et al.
Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease.
 Ann Neurol 1990;28:57-64.

17 Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski PL, Guarda L, Robinson RG, et al.
Reliability, validity, and clinical correlates of apathy in Parkinson’s disease.
 J Neuropsychiatry Clin Neurosci 1992;4:134-9.

18 Menza MA, Sage J, Marshall E, Cody R, Duvoisin RG.
Mood changes and "on-off" phenomena in Parkinson’s disease.
 Mov Disord 1990;5:148-51.

19 Jagust WJ, Reed BR, Martin EM, Eberling JL, Nelson-Abbott RA.
Cognitive function and regional cerebral blood flow in Parkinson’s disease.
 Brain 1992;115:521-37.

20 Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ.
Depression in Parkinson’s disease: a positron emission study.
 Br J Psychiatry 1994;165:333-9.

21 Rubin AJ, Kurlan R, Schiffer R, et al.
Atypical depression and Parkinson’s disease (abstract).
 Ann Neurol 1986;20:150.

22 Menza MA, Robertson-Hoffman DE, Bonapace AS.
Parkinson’s disease and anxiety: comorbidity with depression.
 Biol Psych 1993;34:465-70.

23 Stein M, Henser IJ, Juncos JL, Uhde TW.
Anxiety disorders in patients with Parkinson’s disease.
 Am J Psychiatry 1990;147:217-20.

24 Lauterbach EC, Duvoisin RC.
Anxiety disorders in familial parkinsonism (letter).
 Am J Psychiatry 1992;148:274.

25 Schiffer RB, Kurlan R, Rubin A, Boer S.
Evidence for atypical depression in Parkinson’s disease.
 Am J Psychiatry 1988;145:1020-2.

26 Menza MA, Mark MH.
Parkinson’s disease and depression: the relationship to disability and personality.
 J Neuropsychiatry 1994;6:165-9.

27 Henderson R, Kurlan R, Kersun JM, Como P.
Preliminary examination of the comorbidity of anxiety and depression in Parkinson’s disease.
 J Neuropsychiatry Clin Neurosci 1992;4:257-64.

28 Vasquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, et al.
Panic attacks in Parkinson’s disease: a long-term complication of levodopa therapy.
 Acta Neurol Scand 1993;87:14-8.

29 Rondot P, deRecondo J, Colgnet A, Ziegler M.
Mental disorders in Parkinson’s disease after treatment with L-dopa.
 Adv Neurol 1984:40.

30 Siemers ER, Shekhar A, Quaid K, Dickson H.
Anxiety and motor performance in Parkinson’s disease.
 Mov Disord 1993;8:501-6.

31 Routh LC, Black JL, Ahlskog JE.
Parkinson’s disease complicated by anxiety.
 Mayo Clin Proc 1987;62:733-5.

32 Marsden CD, Parkes JD.
Bromocriptine in parkinsonism.
 Lancet Aug 1976;21;2(7982):419-20.

33 Heninger GR, Charney DS.
Monoamine receptor systems and anxiety disorders.
 Psychiatr Clin North Am 1988;11:309-26.

34 Nutt D, Lawson C.
Panic attacks: a neurochemical overview of models and mechanisms.
 Br J Psychiatry 1992;160:165-78.

35 Agid Y, Cervera P, Hirsch E, Javoy-Agid F, Lehericy S, Raisman R.
Biochemistry of Parkinson’s disease 28 years later: a critical review.
 Mov Disord 1989;4 (suppl 1):5126-44.

36 Weiner WJ, Lang AE.
Movement Disorders: A Comprehensive Survey.
 Mount Kisco, NY: Futura 1989.

37 Charney DS, Heninger GR.
Abnormal regulation of noradrenergic function in panic disorders: effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder.
 Arch Gen Psychiatry 1986;43:1042-54.

38 Villeneuve A, Berlan M, Lafontan M, Caranobe C, Boueu B, Rascol A.
Platelet alpha-2-adrenoceptors in Parkinson’s disease: decreased number in untreated patients and recovery after treatment.
 Eur J Clin Invest 1985;15:403-7.

39 Cash R, Ruberg M, Raisman R, Agid Y.
Adrenergic receptors in Parkinson’s disease.
 Brain Res 1984;322:269-75.

40 Berlan M, Rascol O, Belin J, Moatti JP, Rascol A, Montastruc JL.
Alpha-2 adrenergic sensitivity in Parkinson’s disease.
 Clin Neuropharmacol 1989;12:138-44.

41 Kurlan R, Lichter D, Schiffer RB.
Panic/anxiety in Parkinson’s disease: yohimbine challenge (abstract).
 Neurology 1989;39(suppl 1):421.

42 Miner CM, Davidson JR.
Biological characterization of social phobia (review).
 Eur Arch Psychiatry Clin Neurosci 1995;244:304-8.

43 Charney DS, Woods SW, Krystal JH, Heninger GR.
Serotonin function and human anxiety disorders.
 Ann NY Acad Sci 1990;600:558-72.

44 Cummings JL.
Depression and Parkinson’s disease: a review.
 Am J Psychiatry 1992;149:443-54.

45 Raisman R, Cash R, Agid Y.
Parkinson’s disease: decreased density 3H-imipramine and 3H-paroxetine binding sites in putamen.
 Neurology 1986;36:556-60.

46 D’Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R.
Aminergic systems in Alzheimer’s disease and Parkinson’s disease.
 Ann Neurol 1987;22:229-36.

47 King R, Mefford I, Wang C, Murchison A, Caligari EJ, Berger PA.
CSF dopamine levels correlate with extroversion in depressed patients.
 Psychiatry Res 1986;19:305-10.

48 Mayleben M, Gariepy J, Tancer M, et al.
Genetic differences in social behavior: neurobiological mechanisms in a mouse model (abstract).
 Biol Psychiatry 1992;31(suppl.):216A.

49 Tancer ME.
Neurobiology of social phobia.
 J Clin Psychiatry 1993;54(suppl.12)26-30.

50 Mikkelson EJ, Deltor J, Cohen DJ.
School avoidance and social phobia triggered by haloperidol in patients with Tourette’s syndrome.
 Am J Psychiatry 1981;138:1572-6.

51 Emmanuel NP, Lydiard RB, Ballenger JC.
Treatment of social phobia with bupropion.
 J Clin Psychopharmacol Aug 1991;11(4):276-7.

52 Strang RR.
Imipramine in treatment of parkinsonism: a double-blind placebo study.
 Br Med J 1965;2:33-4.

53 Laitinen L.
Desipramine in treatment of Parkinson’s disease.
 Acta Neurol Scand 1969;45:109-13.

54 Andersen J, Aabro E, Gulman N, Hjelmsted A, Pedersen HE.
Antidepressive treatment in Parkinson’s disease: a controlled trial of the effect of nortriptyline in patients with Parkinson’s disease treated with L-dopa.
 Acta Neurol Scand 1980;62:210-9.

55 Denmark JC, David JDP, McComb SG.
Imipramine hydrochloride (Tofranil) in parkinsonism: a preliminary report.
 Br J Clin Prac 1961;15:523-4.

56 Randrup A, Munkvad I, Fog J, et al.
Mania, depression, and brain dopamine.
 In: Essman WB, Vlazelli L, Fairfield CT, Robert B, eds. Current Developments in Psychopharmacology. Luce 1975:206-48.

57 Halaris AE, Belendiuk KT, Freedman DX.
Antidepressant drugs affect dopamine uptake.
 Biochem Pharmacol 1975;24:1896-7.

58 Ghosh PK, Hrdina PD.
Effects of tricyclic antidepressants on the content and metabolism of dopamine in the rat striatum.
 Can J Physiol Pharmacol 1976;55:383-8.

59 Alpers HS, Himwich HE.
Effects of repeated daily injections of imipramine on brain levels of serotonin, 5-hydroxyindoleacetic acid, norepinephrine and dopamine (abstract).
 Federation Proceedings 1971;30:672.

60 Meara RJ, Bhowmick BK, Hobson JP.
An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson’s disease.
 Journal of Serotonin Research 1996;4:243-9.

61 Hauser RA, Zesiewicz TA.
Sertraline for the treatment of depression in Parkinson’s disease.
 Mov Disord 1997;12:756-7.

62 Wittgens W, Donath O, Trenckmann U.
Treatment of depressive syndromes in Parkinson’s disease with paroxetine (abstract).
 Mov Disord 1997;12:128.

63 Goetz CG, Tanner CM, Klawans HL.
Bupropion in Parkinson’s disease.
 Neurology 1984;34:1092-4.

64 Jansen Steur E.
Increase of Parkinson disability after fluoxetine medication.
 Neurology 1993;43:211-3.

65 Chouinard G, Sultan S.
A case of Parkinson’s disease exacerbated by fluoxetine (letter).
 Hum Psychopharmacol 1992;7:63-6.

66 Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E.
Parkinsonism exacerbated by paroxetine (letter).
 Neurology; 1994;44:406.

67 Sternbach H.
The serotonin syndrome.
 Am J Psychiatry 1991;148:705-13.

68 Tate JL.
 Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.
 Am J Psychiatry 1989;146:399-400.

69 Feigher JP, Boyer WF, Tyler DL, et al.
Adverse consequences of fluoxetine-MAOI combination therapy.
 J Clin Psychiatry 1990;51:222-5.

70 Suchowersky Q, DeVries J.
Possible interactions between deprenyl and Prozac.
 Can J Neurol Sci 1990;17:352-3.

71 Montastruc JL, Chamontin B, Senard JM, et al.
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline (letter).
 Lancet 1993;341:555.

72 Richard I, Kurlan R, Tanner C, et al.
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease: Parkinson Study Group.
 Neurology 1997;48:1070-7.

73 McGrath PJ, Stewart JW, Quitkin FM.
A possible L-deprenyl-induced hypertensive reaction.
 J Clin Psychopharmacol 1989;9:310-1.

74 Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T.
A controlled study of the antidepressant efficacy and side effects of deprenyl: a selective monoamine oxidase inhibitor.
 Arch Gen Psychiatry 1989;46:45-50.

75 Boyson SJ.
Psychiatric effects of selegiline (letter).
 Arch Neurol 1991;48:902.

76 Sunderland T, Cohen R, Molchan S, Lawlor BA, Mellow AM, Newhouse PA.
High-dose selegiline in treatment-resistant older depressive patients.
 Arch Gen Psych 1994;51:607-15.

77 Agnoli A, Ruggieri S, Denaro A, Lelli A.
Parkinson’s disease improvement after the addition of levodopa-carbidopa to anticholinergic treatment. An open controlled study.
 Acta Neurol (Napoli) Oct; 1978;33(5):436-42.

78 Colonna L, Petit M, Lepine JP.
Bromocriptine in affective disorders. A pilot study.
 J Affect Disord Sep 1979;1(3):173-7.

79 Nordin C, Siwers B, Bertilsson L.
Bromocriptine of depressive disorders: clinical and biochemical effects.
 Acta Psychiatr Scand 1981;64:25-33.

80 Silverstone T.
Response to bromocriptine distinguishes bipolar from unipolar depressions.
 Lancet 1984;1:903-4.

81 Waehrens J, Gerlach J.
Bromocriptine and imipramine in endogenous depression: a double-blind controlled trial in outpatients.
 J Affect Disord 1981;3:193-202.

82 Bouras N, Bridges PK.
Bromocriptine in depression.
 Curr Med Res Opin 1982;8(3):150-3.

83 Theohar C, Fischer-Cornelssen K, Brosch H, Fischer EK, Petrovic D.
A comparative, multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression.
 Arzneimittelforschung 1982;32(7):783-7.

84 Post RM, Gerner RH, Carman JS.
Effects of a dopamine agonist piribedil in depressed patients.
 Arch Gen Psychiatry 1978;35:609-15.

85 Schwab RS, England AC, Poskanzer DC, Young RR.
Amantadine in the treatment of Parkinson’s disease.
 J Am Med Association 1969;208:1168-70.

86 Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP.
Controlled trial of amantadine hydrochloride in Parkinson’s Disease.
 Lancet 1970;1:259-62.

87 Huber SJ, Freidenberg DL, Paulson GW, Shuttleworth EC, Christy JA.
The pattern of depressive symptoms varies with progression of Parkinson’s disease.
 J Neurol Neurosurg Psychiatry 1990;53:275-8.

88 Vale S, Espejel MA, Dominguez JC.
Amantadine in depression.
 Lancet 1971;21:437.

89 Rizzo M, Bioandrate P, Tognoni G, Morselli PL.
Amantadine in depression: relationship between behavioral effects and plasma levels.
 Eur J Clin Pharmacol 1973;5:226-8.

90 Bode L, Ludwig H.
Clinical similarities and close genetic relationship of human and animal Borna disease virus.
 Arch Virol Suppl 1997;13:167-82.

91 Rott R, Herzog S, Fleischer B, Winokur H, Amsterdam J, Dyson W, et al.
 Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders.
 Science 1985;228:755-6.

92 Ferszt R, Kuhl KP, Bode L, Severus EW, Winzer B, Berghofer A, et al.
Amantadine revisited: an open trial of amantadinesulfate treatment in chronically depressed patients with Borna disease virus infection.
 Pharmacopsychiatry Jul 1999;32(4):142-7.

93 Bouckoms A, Mangini L.
Pergolide: an antidepressant adjuvant for mood disorders?
 Psychopharmacol Bull 1993;29(2):207-11.

94 Szegedi A, Hillert A, Wetzel H, Klieser E, Gaebel W, Benkert O.
Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses.
 Clin Neuropharmacol 1997;20(1):S36-S45.

95 Goodman WK, Corrigan M, Evans D.
Pramipexole in the treatment of major depression.
 Abstract presented at the congress of "European federation of Neurological Societies", Siviglia, Spain, September 1998.

96 Goldberg JF, Frye MA, Dunn RT.
Pramipexole in refractory bipolar depression.
 Am J Psychiatry May 1999;156(5):798.

97 Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, et al.
Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy.
 Eur Neuropsychopharmacol 1997;7:65-70.

98 Mjones H.
Paralysis agitans: a clinical and genetic study.
 Acta Psychiatr Neurol Scand 1949;54:1-195.